Chosen wisely: Grail, Quest team up on cancer blood test Grail has tapped testing giant Quest Diagnostics to help roll out its upcoming multi-cancer blood test, expected to launch in the coming months. In addition to offering the company’s Galleri test at its more than 2,000 locations, Quest will provide blood collection services through at-home […]
Read More
Breast cancer: is milk a risk factor? Breast cancer has now overtaken lung cancer as the world’s most commonly diagnosed cancer, and as the leading cause of cancer-related deaths for women in many countries. While genetics can certainly increase risk of the disease, for most women lifestyle factors, such as alcohol or being overweight or […]
Read More
FDA grants fast track designation to GEN-1 for advanced ovarian cancer February 23, 2021 1 min read ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS We were unable […]
Read More
Genmab Publishes 2020 Annual Report Company Announcement Copenhagen, Denmark; February 23, 2021 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2020. Below is a summary of business progress in 2020, financial performance for the year and the financial outlook for 2021. The full report is attached as a PDF […]
Read More
Pursue 8 E (Uploaded): Nephropathology- Plasma cell Dyscrasia. Nephropathology Plasma cell Dyscrasia. Lecture conducted by: Dr. Suvradeep Mitra MD. (PGIMER- Chandigarh), DM- Histopathology (PGIMER- Chandigarh) PDCC (ICP) in Renal and Transplant Pathology (PGIMER, Chandigarh). Asst Professor in the Dept of Pathology and Lab Medicine, AIIMS, Bhubaneswar More than 70 publications in indexed National and International […]
Read More
PET-CT vs MRI in multiple myeloma Philippe Moreau, MD from the University Hospital of Nantes, Nantes, France gives an overview of a prospective comparative study on PET-CT and MRI in multiple myeloma (MM). The primary endpoint of the trial (NCT01309334) was to compare MRI and PET-CT in regard to the number of bone lesions at […]
Read More